Search - tctmd.com

Displaying 241 - 260 of 329

Sort: Relevancy | Date

News Daily News

Apixaban es Rentable comparado con Warfarina o Aspirina

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

News Daily News

荟萃分析：药物治疗基础上联合应用PCI并未改善心肌缺血患者预后

Yael L. Maxwell

December 08, 2013

News Daily News

Meta-analysis: PCI Adds No Benefit to Medical Therapy in Patients with Proven Ischemia

Yael L. Maxwell

December 08, 2013

News Daily News

Meta Análisis: La PCI No añade Beneficio alguno al Tratamiento Médico en Pacientes con Isquemia Demostrada

Yael L. Maxwell

December 08, 2013

Presentation

The Cost of TAVR: Where Can We Save?

Presenter: David Cohen

October 29, 2013

Presentation TCT 2013

A Critical Analysis of Functional Improvement after TAVR in the CoreValve US Extreme Risk Study

Presenter: David Cohen

October 29, 2013

News Conference News TCT 2013

SYNTAX Cost-effectiveness Analysis Supports Existing Guidelines

October 29, 2013

Presentation TCT 2013

Stop the Debate! Selective Use of BMS Is Rational and Cost-Effective

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

Transradial Intervention in STEMI: How Long Can We Delay Door-to-Balloon Time?

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

A Synthesis of the Global Literature on TAVR Cost-effectiveness

Presenter: David Cohen

October 28, 2013

News Daily News

Early QOL Advantage of CABG Over PCI for Diabetic Patients Disappears After 2 Years

L.A. McKeown

October 15, 2013

News Daily News

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

July 25, 2013

News Daily News

En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida

July 25, 2013

Presentation TVT 2013

Can We Afford TAVR? Impact on US Hospitals and Health Systems: Lessons from PARTNER and Beyond

Presenter: David Cohen

June 13, 2013

Presentation TVT 2013

TAVR Cost-effectiveness and Reimbursement: A Global Gordian Knot

Presenter: David Cohen

June 12, 2013

News Daily News

新型抗凝血剂在心房纤维颤动病患治疗中比华法林抗凝血剂更具性价比(2)

Caitlin E. Cox

May 13, 2013

News Daily News

Novel Anticoagulants Cost-Effective vs. Warfarin in A-fib Patients

Caitlin E. Cox

May 13, 2013

Presentation TCTAP 2013

Can We Afford TAVR? Economic Insights from the PARTNER Trial

Presenter: David J. Cohen

April 25, 2013

Advertisement

Apixaban es Rentable comparado con Warfarina o Aspirina

Apixaban Cost-Effective Compared with Warfarin or Aspirin

荟萃分析：药物治疗基础上联合应用PCI并未改善心肌缺血患者预后

Meta-analysis: PCI Adds No Benefit to Medical Therapy in Patients with Proven Ischemia

Meta Análisis: La PCI No añade Beneficio alguno al Tratamiento Médico en Pacientes con Isquemia Demostrada

The Cost of TAVR: Where Can We Save?

A Critical Analysis of Functional Improvement after TAVR in the CoreValve US Extreme Risk Study

SYNTAX Cost-effectiveness Analysis Supports Existing Guidelines

Stop the Debate! Selective Use of BMS Is Rational and Cost-Effective

Transradial Intervention in STEMI: How Long Can We Delay Door-to-Balloon Time?

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

A Synthesis of the Global Literature on TAVR Cost-effectiveness

Early QOL Advantage of CABG Over PCI for Diabetic Patients Disappears After 2 Years

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida

Can We Afford TAVR? Impact on US Hospitals and Health Systems: Lessons from PARTNER and Beyond

TAVR Cost-effectiveness and Reimbursement: A Global Gordian Knot

新型抗凝血剂在心房纤维颤动病患治疗中比华法林抗凝血剂更具性价比(2)

Novel Anticoagulants Cost-Effective vs. Warfarin in A-fib Patients

Can We Afford TAVR? Economic Insights from the PARTNER Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content